Philip Morris International Inc (PM)
PM trades on NYSE in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/0001628280-26-005939-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PM on NYSE |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001413329 |
| SEC industry code | Cigarettes |
| Incorporated in | VA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $40.6B |
| Net income | $11.3B |
| Operating income | $14.9B |
| Net margin | 27.9% |
| Operating margin | 36.6% |
| Revenue growth | +7.3% |
| Cash | $4.9B |
| Total assets | $69.2B |
| P/E (computed) | 26.9× |
| P/S (computed) | 7.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-23 |
| Cash and burn | $6.7B cash; operating cash flow $3.8B a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,558,655,629 (2026-10-16); 1,556,638,749 a year earlier; 1,552,405,991 three years earlier. | Cover page 2026-10-16 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-08-03 |
| Auditor | PricewaterhouseCoopers AG, Lausanne, Switzerland | PCAOB Form AP 2026-02-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $28.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $11.4B | $3.3B | $5.4B | $6.7B | $47.6B | $43.1B | 10-Q 2026-10-23 |
| Q2 2026 2026-06-30 | $11.2B | $2.8B | $5.5B | $6.0B | $49.1B | $42.5B | 10-Q 2026-07-24 |
| Q1 2026 2026-03-31 | $10.1B | $2.4B | -$399.0M | $5.5B | $51.9B | $41.5B | 10-Q 2026-04-24 |
| Q4 2025 2025-12-31 | $10.4B | $2.1B | $4.7B | $4.9B | $48.8B | $40.6B | 10-K 2026-02-06 |
| Q3 2025 2025-09-30 | $10.8B | $3.5B | $4.5B | $4.0B | $50.1B | $40.0B | 10-Q 2026-10-23 |
| Q2 2025 2025-06-30 | $10.1B | $3.0B | $3.4B | $4.1B | $51.5B | $39.1B | 10-Q 2026-07-24 |
| Q1 2025 2025-03-31 | $9.3B | $2.7B | -$350.0M | $4.4B | $49.6B | $38.4B | 10-Q 2026-04-24 |
| Q4 2024 2024-12-31 | $9.7B | -$579.0M | $4.0B | $4.2B | $45.7B | $37.9B | 10-K 2026-02-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-04-28 |
| Latest annual report | 10-K | 2026-02-06 |
| Latest quarterly / interim | 10-Q | 2026-10-23 |
| Latest current report | 8-K | 2026-10-21 |
| Latest proxy | DEFA14A | 2026-03-31 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | -0.2% |
| 3 months | +5.3% |
| Year to date | +24.0% |
| 1 year | +28.2% |
| From 52-week high | -5.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BTI | British American Tobacco Industries p.l.c. Common Stock ADR | $62.11 | +0.36% | $134.2B |
| MO | Altria Group Inc. | $78.90 | +0.33% | $131.2B |
| DFTX | Definium Therapeutics Inc. Common Shares | $30.16 | -5.99% | $4.1B |
| RGC | Regencell Bioscience Holdings Limited | $4.72 | -4.45% | $2.3B |
| TRLV | Trulieve Cannabis Corp. Subordinate Voting Shares | $10.33 | -5.23% | $2.0B |
| RLX | RLX Technology Inc. | $1.53 | -1.92% | $1.9B |
| CRON | Cronos Group Inc. Common Share | $3.27 | -3.25% | $1.2B |
| OBIO | Orchestra BioMed Holdings Inc. | $7.12 | -1.79% | $560.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier